an volunteers treated with Revamilast suggests a good ex-vivo inhibition of the inflammatory marker TNF-α with maximum inhibition upto 93%. Based on these results and animal model data, it is expected that Revamilast would be beneficial in a variety of inflammatory disorders. Additionally, Revamilast does not appear to be metabolized to carcinogenic metabolites (ADCP N-oxide and ADCP N-oxide epoxide); and plasma samples from a Phase 1 study analyzed for such metabolites of Revamilast, showed no levels were detected in human plasma.
With the completion of several Phase I studies, Glenmark has initiated a global Phase IIb trial for Revamilast in patients with Asthma. Glenmark has already received approval from respective authorities in the UK, Poland, India and Czech Republic to conduct Phase IIb studies. Regulatory submissions have also been completed in Russia. The primary objective of this 12-week, double blind, placebo controlled, dose range finding study is to evaluate the effects of Revamilast at three doses on lung function (FEV1) in nearly 450 patients with chronic persistent Asthma.
Glenmark has also initiated another global Phase IIb trial with Revamilast in patients with Rheumatoid Arthritis. Glenmark has already received approval from the MHRA, UK, India, Poland and the Philippines to conduct Phase IIb studies for Rheumatoid Arthritis. Regulatory submissions have also been completed in Sri Lanka. The objective is to determine the efficacy of three doses of Revamilast compared to placebo in the treatment of more than 400 patients with active Rheumatoid Arthritis who showed an inadequate response to methotrexate.
In parallel to these two clinical studies, Glenmark is also conducting various other clinical and non-clinical studies to ensure timely entry into Phase III trials. Glenmark intends to initiate Phase III trials for at least one indication in the second half of FY 2012-13
PDE4 inhibitors (Impact o
Page: 1 2 3 4 Related biology technology :1
|SOURCE Glenmark Pharmaceuticals Ltd.|
Copyright©2010 PR Newswire.
All rights reserved
. Glenmark Announces the Discovery of a Novel Chemical Entity GRC 17536, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally2
. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials3
. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London4
. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy5
. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies6
. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF7
. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine8
. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis9
. Metabolex Initiates Phase 2 Trial of Arhalofenate10
. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline11
. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee